Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:14:45 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - http://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q0.23.56·4.300.13.76+0.071.9743.32,5414,4493.73  3.77  3.62510.45  3.2519:39:3007:3015 min RT 2¢

Recent Trades - Last 10 of 4449
Time ETExPriceChangeVolume
19:39:30Q3.790.101
19:30:24Q3.790.1050
17:54:04Q3.790.105
17:47:06Q3.840.151
16:16:58Q3.700.01830
16:05:47Q3.710.021
16:02:26Q3.760.075,370
16:02:23Q3.760.072,190
16:02:21Q3.760.07133
16:01:31Q3.760.071,121

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
2024-04-11 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
2024-03-25 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
2024-03-19 15:50U:AVXLNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL
2024-03-18 07:30U:AVXLNews ReleaseAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX(TM)3-71 in Schizophrenia
2024-02-26 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
2024-02-07 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports ‚  Fiscal 2024 First Quarter Financial Results and Provides Business Update
2024-02-01 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
2024-01-24 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Publication of ANAVEX ‚ ®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX ‚ ®3-71 in Humans
2024-01-16 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX ‚ ®3-71 in Schizophrenia
2024-01-08 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX ‚ ®2-73) for Treatment of Neurodevelopmental Disorders
2024-01-03 07:30U:AVXLNews ReleaseAnavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:00U:AVXLNews ReleaseAnavex Life Sciences Provides an Update on Rett Syndrome Program
2023-12-20 07:30U:AVXLNews ReleaseAnavex Announces First Entire Clinical Gene Pathway Data of ANAVEX ‚ ®2-73 from AVATAR Study in Patients with Rett Syndrome
2023-12-19 07:30U:AVXLNews ReleaseAnavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer ¢ € ™s Disease
2023-11-27 08:00U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
2023-11-24 08:00U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
2023-11-22 08:00U:AVXLNews ReleaseAnavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX ‚ ®2-73) for Treatment of Insomnia or Anxiety
2023-11-20 08:00U:AVXLNews ReleaseAnavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer ¢ € ™s Disease to European Medicines Agency (EMA)
2023-11-06 08:00U:AVXLNews ReleaseAnavex Life Sciences Appoints Senior VP of Regulatory Affairs